OTC · Healthcare
Vaxart, Inc. (VXRT)
As-reported financials and recent SEC filings for Vaxart, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$237.3M
Net income
$16.3M
Net margin
6.9%
Diluted EPS
$0.07
ROE
18.6%
P/E (TTM)
3.4×
Market cap
$130.7M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $237.3M | $28.7M | $7.4M | $107,000 | $892,000 |
| Gross profit | — | — | — | — | — |
| Operating income | $18.1M | $-66.3M | $-83.3M | $-114.6M | $-72.8M |
| Net income | $16.3M | $-66.9M | $-82.5M | $-107.8M | $-70.5M |
| Diluted EPS | $0.07 | $-0.33 | — | — | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-26
View on EDGAR →DEFA14A2026-06-26
View on EDGAR →DEFA14A2026-06-26
View on EDGAR →DEFA14A2026-06-26
View on EDGAR →DEFA14A2026-06-26
View on EDGAR →DFAN14A2026-06-22
View on EDGAR →DEFA14A2026-06-16
View on EDGAR →DEFA14A2026-06-16
View on EDGAR →Go deeper on VXRT
Search Vaxart, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.